Multiple myeloma: the National University Hospital (NUH) experience.
The aim of this retrospective study was to define the characteristics of local patients with multiple myeloma. Twenty-nine de novo cases were accrued from October 1986 to January 1992 at the National University Hospital of Singapore. Features like median age of presentation, sex distribution, the incidence of IgG, IgA and light chain subtypes were similar to published data. However IgD myeloma appeared to be more common here and it tended to be more advanced at presentation. Objective response rate to treatment with the melphalan-prednisolone combination was about 40% with a median survival of 18 months.
Lim
H L
HL
Department of Medicine, National University Hospital, Singapore.
Teo
C P
CP
Wong
K
K
Kuperan
P
P
Suri
R
R
Tan
Y O
YO
Kueh
Y K
YK
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007072:Immunoglobulin D / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007147:Immunoglobulin Light Chains / Q000032:analysis; D015994:Incidence; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D017678:Sex Distribution; D012846:Singapore / Q000453:epidemiology; D015996:Survival Rate
D007070:Immunoglobulin A; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D007147:Immunoglobulin Light Chains; D011239:Prednisolone; D008558:Melphalan